Newborn Screening

Advocate with Us

If you’d like to advocate in your region, email us at and let’s work together! A local voice is the most influential in making change and we can help you prepare with slides and a customized presentation. Another way to advocate is to tell your story of GAMT and how it’s impacted you or a loved one’s life. Tag your stories on social media with #addGAMT or make a donation to support our work here.

What is Newborn Screening?

Newborn screening (NBS) is the collection of blood drops from a newborn’s heel onto a card of filter paper to screen for an approved group of disorders that require immediate treatment. The blood is usually collected between 24-48 hours after birth and sent to a government-run (or government-contracted) lab for testing.

PKU is the most well-known disorder as it was the first disorder screened for, beginning in the 1960s, but most NBS panels now screen for many disorders. In the United States, the Secretary of Health and Human Services maintains a Recommended Uniform Screening Panel (RUSP) of disorders that is provided as guidance to the individual states. States are not required to follow the RUSP recommendations except in the case of those states that have passed legislation committing themselves to follow the RUSP. Inclusion on the RUSP is a major milestone for our community, achieved January 2023 and after nearly 7 years of advocacy work by the ACD and partners. RUSP inclusion increases the likelihood of GAMT being screened for, not only in the U.S., but in countries worldwide. This is evident in recent advancements seen on the map above.

ACD is actively advocating for the expansion of GAMT newborn screening and supports research of CTD newborn screening as well. AGAT newborn screening is theoretically possible with the measurement of GAA (also referred to as “GUAC” in newborn screening labs) and Creatine levels, the same levels measured in GAMT screening, but the sensitivity of the instruments currently available is not great enough to differentiate a “low-normal” and an AGAT level. There is hope that improvements in technology will make screening for AGAT possible.

Get Involved!

ACD supports the validation of testing for GAMT Deficiency and the research of plausibility for CTD and AGAT newborn screening by assisting interested labs in obtaining a very small portion of patients’ dried blood spots (DBS) that were collected shortly after birth. Many laboratories retain these DBS for years. If you’d like to help in this effort, please complete this form so that we can check if your child’s spot is available. If it is available, you will be contacted by ACD. You will decide if you wish to consent in the particular research being done. Filling out this form does not give us permission to act on your behalf. It does not allow us to use your child’s DBS without your consent. We will not share your information with anyone for any reason. The intent of this form is to identify the availability of DBS and allow you to decide what research you will support.

Additional NBS Info and Links

  1. Publications & Materials

    September 1, 2023

    POSTER: Improved outcomes in early treated GAMT deficiency: A sibling study

    ACD assisted Dr. Andreas Schulze in recruitment of sibling pairs for his study on the outcomes of early treated GAMT deficiency. He presented an informational poster on his findings at the Society for the Study of Inborn Errors of Metabolism (SSEIM) 2023 Annual Symposium in Jerusalem. This poster clearly shows the benefits of an early vs. late diagnosis of GAMT deficiency.
    View the Poster

    February 17, 2022

    Modernization of Newborn Screening Study

    ACD continues to contribute to newborn screening. Kim Tuminello, Founder and Director of Advocacy, participated in this study on modernizing newborn screening.  See how a group of stakeholders discuss the impact of newborn screening at the federal and state levels, and the real possibility of 60 new gene therapies for rare diseases.
    Read the Report

    July 29, 2021

    Prospective identification by neonatal screening of patients with guanidinoacetate methyltransferase deficiency

    New York and Utah NBS programs share data on their screenings that ultimately resulted in the first and second diagnoses in the world of GAMT deficiency by newborn screening. ACD Executive Director, Heidi Wallis, is a co-author.

    See the abstract on PubMed.

NBS Advocacy Updates

  1. Fall 2022 Update

    The last year has brought great advances in GAMT newborn screening efforts. A unanimous vote of the ACHDNC (a committee that advises the U.S. Secretary of Health and Human Services, Dr. Xavier Becerra) to advance GAMT toward addition to the list of disorders recommended for newborn screening (the “RUSP”) is the win we had been looking for since GAMT newborn screening advocacy began more than ten years ago. ACD has written to Dr. Becerra (see the letter here) in support of a timely approval of GAMT. After his anticipated signature, no later than November of this year, it will be up to individual states to approve local legislation to add GAMT to their newborn screening panels. It is anticipated that states that usually follow early adoption such as California, Texas, Florida, Iowa, Mississippi, Maryland and North Carolina will add GAMT screening within 2-3 years. They would be joining three other states already screening- Utah, New York and Michigan.

    Outside of the U.S.- British Columbia, Canada, has been screening for GAMT for several years. Ontario, Canada is very close to adding GAMT to their panel as well. The state of Victoria, Australia has been testing for GAMT since 2002 and recently found their first baby in spring of 2022! A family physician, ACD Global Ambassador, and CCDS parent, is now advocating for adoption of GAMT in other areas of Australia.

    PerkinElmer featured the story of another GAMT family in their recent company-wide meeting and named ACD the chosen charity of the event. They are also preparing to release a GAMT video to all of their testing labs throughout the world.

    We encourage any GAMT supporters interested in advancing their local newborn screening panel to include GAMT to reach out to ACD and learn how we can work together! Email for more information.

  2. Spring 2021 Update

    There are so many exciting things happening in the world of newborn screening for our community!  With the finding of Baby Tribe, diagnosed with GAMT during the routine newborn screening in Utah, ACD will again nominate GAMT for the United State’s Recommended Uniform Screening Panel (RUSP).  In 2016, Drs. Nicola Longo and Marzia Pasquali, along with ACD, nominated GAMT to be included in the RUSP, but lost by one vote because of a criteria that had just been added, of one prospective baby being found during routine newborn screening. We will be submitting the nomination package in the hopes of a vote during the May 2021 meeting of the Advisory Committee of Heritable Disorders in Newborns and Children (ACHDNC). We feel hopeful that GAMT will be voted forward to the Secretary of Health and Human Services for final approval.

    The best news is that the newly diagnosed baby Woodward will be able to live a typical healthy life because he has been receiving treatment for GAMT since  birth. His parents, Stewart and Becky Tribe, have shared their experience of learning that their new baby has a rare genetic disorder.  Our entire community had been waiting for this baby to be discovered. What a lucky decision these parents made, to move to one of only a few states that currently test for GAMT.  According to Stewart Tribe, “During the COVID lock-down in April, we decided to make the move from California to Utah. It was an impulsive decision at the time that we now recognize as nothing short of stars aligning for our family and newborn son, Woodward.”

    As the news of baby Woodward spreads, state labs are taking notice. The Association of Public Health Laboratories (APHL) meeting in January, held a discussion on GAMT led by Kim Hart, Utah Newborn Screening Program Manager. Hart, along with Drs. Marzia Pasquali and Nicola Longo, have teamed up and are writing a paper, sharing data from screening for GAMT in Utah since 2015.

    Once GAMT is added to the RUSP, advocacy at the state level will be needed to encourage state newborn screening programs to follow this recommendation and add GAMT in a timely manner. ACD is preparing a presentation on the importance of adding GAMT to state newborn screening. This presentation will help provide the tools needed to families wishing to become involved and help ACD advocate in their home states. Please contact if you are interested in helping with this important work.

  3. Spring 2020 Update

    In the last several years, ACD has advocated for GAMT to be added to the RUSP, (Recommended Uniform Screening Panel) which is the U.S. Federal recommendation for Newborn Screening. Currently, GAMT is being screened in Utah and New York. Michigan is in the process of adding the condition. Without being approved by the ACHDNC (Advisory Committee of Heritable Disorders in Newborns and Children) to be on the RUSP, our efforts will continue to be state by state. Our goal is still to have one baby identified during newborn screening, to meet the criteria to be added to the RUSP.

    However, there has been one more obstacle placed before us. As of September 30, 2019, the Federal newborn screening programs expired. The House passed the Newborn Screening Saves Lives Reauthorization Act in July 2019, but currently, the bill is held up in the Senate. The bill is held up due to a proposed amendment that would require parents to opt-in to allow their newborn’s unidentified dried blood spot (DBS) to be used for research, which experts feel would break down the entire newborn screening system. Public health laboratories and scientific researchers need DBS to conduct life-saving research to improve the current tests and work to develop new treatments for the thousands of rare diseases still without a cure. Unfortunately, complying with this amendment would place a high burden on hospitals that would likely choose not to participate in the collection of DBS. Studies have demonstrated that 90%-99% of parents would choose to opt-in, but at times only half of the parents would be asked by hospital staff due to the compliance burden. The Senate Bill Provisions include reauthorizing the Health Resources and Services Administration (HRSA) state grants to expand and improve screening programs, provide educational resources to parents and health care providers, and improve follow-up care for infants with a detected condition. It would also reauthorize the ACHDNC, which again, provides the list of conditions to be screened.

    This past month, ACD was represented at Rare Disease Week on Capitol Hill by Celeste Graham and Gina Opperman Nichols. These two, along with 600 patient advocates, were asking their senators to get behind the bill. They specifically met with Senator Burr from North Carolina, and we are hopeful that the Senate will be passing it, sooner than later!

    *Since this article has been written, the advisory committee has been approved in March of 2020, however, the reauthorization of the NBS act has yet to be approved.

    Kim Tuminello
    ACD Director of Advocacy

  4. Spring 2019 Update

    ACD is pleased to report tremendous momentum in GAMT newborn screening in 2018. The state of New York began testing for GAMT in October 2018. Almost 250,000 babies are born in New York each year. Michigan approved the addition of GAMT in 2018 and is set to begin testing within the first quarter of 2019. Michigan has 115,000 births each year. Including the state of Utah, which began testing in 2015, there will be over 565,000 babies tested for GAMT annually in the U.S.

    A family in the United Kingdom began a petition to request the addition of GAMT to the UK’s newborn screening. Hana Young, midwife, and mother of a child diagnosed with GAMT, was highlighted on the BBC, speaking on the importance of catching this devastating disorder early on in life. Read the article here.

    In November of 2018, the Robinson family spoke in front of the Missouri newborn screening committee to recommend the addition of GAMT to their list of screened disorders and highlighted the importance of early detection of the disorder. Members of our SMAB, Dr. Nicola Longo and Dr. Andreas Schulze, also speak on our behalf in the states of New York and Missouri.

    2019 Newborn Screening Plan

    ACD plans to aggressively advocate in many more states in 2019, including Georgia, Missouri, Wisconsin, Ohio, and Minnesota. These are states that do not require GAMT to be approved by the federal government’s advisory committee. They are able to choose the disorders they screen for on a state level.

    In order to meet the requirement of having a treatment protocol for the RUSP, ACD is hosting a satellite session at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting to reach a consensus on treatment recommendations. This session is being held on April 8 in Seattle, WA.

    ACHDNC Chairman—Dr. Joseph Bocchini mentioned to ACD Board Members, Kim Tuminello and Heidi Wallis, that there could possibly be alternative ways of proving the reliability of GAMT testing technologies without having to identify an actual newborn through active screenings. ACD will continue to work on this possibility while also hoping for the best in 2019 in the states of Utah, New York, and Michigan.

    Kim Tuminello
    ACD Director of Advocacy

  5. Fall 2017 Update

    There are so many wonderful things happening in the world of newborn screening. Not only is GAMT being recognized as a viable newborn screening addition in several states in the U.S. and locations abroad, but newborn screening technology advancements are being made to detect more and more disorders, and to do so quickly! The idea of every family having the information at birth, of their child’s disease, as opposed to the average 7-year odyssey that most families currently endure, is a concept that is not that far off in the future, but of course, legislation and costs are also a part of the equation. There are those in the world that might argue that they are not interested in knowing, however, I would bet that if they could know upfront why their child would struggle to gain weight, miss milestones, or develop epilepsy, they would opt in for the information.

    Currently, ACD is advocating in many states for GAMT to be added to the state’s newborn screening program. In just this past month, members of ACD have attended newborn screening meetings in Georgia, Utah, and Michigan (with a final vote in Michigan to be held on November 13th), and have sent consents to the state of New York to obtain their child’s blood spots to support New York’s research into screening. These spots will help prove that newborn blood spots show the elevated Guanidinoacetate (GAA) that is required for GAMT to be added to the Newborn Screening panel. Each state has its own process to prepare their lab for GAMT testing. They must also have the personnel to conduct the testing and a plan in place for the follow-up with families when an elevated GAA is detected. And of course, they need to understand the costs of adding this to their current newborn screening.

    If you are interested in seeing how long your state typically holds blood spots, to know if your child’s might be available to help with future states needing to validate their testing (including New York which is still in need of more samples), visit NewSteps and click on your state, then “Policies”, then “Dried Blood Spot Retention Time”. If your state still has your child’s spot, and you are interested in helping the state of New York, or others, please email, and you will be given further information. Many states are trying to ramp up their retention times, so if you are borderline, even within a year or two, please check with your state to confirm.

    The U.S. Advisory Committee on Heritable Disorders in Newborns and Children has indicated that as soon as ONE BABY with GAMT is identified through newborn screening, they will recommend all states begin screening for GAMT. This will change the future for all Creatine Deficiencies in awareness, research, and hopefully one day for a treatment or a cure! The sooner, the better.

    Kim Tuminello
    ACD Director of Advocacy

  6. Spring 2017 Update

    ACD is continuing to work towards all babies one day being screened for Creatine Deficiencies, not only in the United States but around the world. Currently, GAMT is under serious consideration in many places amongst physicians and researchers since it has a safe and affordable treatment. As many of you know, GAMT has come very close to being recommended to the U.S. national newborn screening program of RUSP (Recommended Uniform Screening Panel) and will be added once one baby is identified on a newborn screen either by an individual state, a pilot program of a state or by another country.

    Currently, there are only a few locations that are screening for GAMT including some provinces in Canada, Australia, and in the United States, Utah is the only state. However, Michigan’s Newborn Screening Metabolic Quality Improvement Committee (MetQIC) used their newly developed condition readiness tool in June to assess the state’s readiness to begin screening for GAMT deficiency. The MetQIC classified GAMT deficiency as “developmental”, and conditions that fall into this category can begin Michigan’s approval process. The MetQIC voted unanimously to forward GAMT deficiency to the Technical Advisory Committee (TAC) for review. When the TAC meets at the end of September, they will review the materials from the MetQIC and vote on whether GAMT deficiency should be forwarded to the Quality Assurance Advisory Committee (QAAC). The QAAC meets in November and will formally vote on whether GAMT deficiency should be added to Michigan’s panel!

    ACD is also currently working on submitting an application for the state of Georgia and anticipates the first meeting to discuss this application to be held in September. We are also pursuing the states of Connecticut, Missouri, Colorado, and a pilot program in New York. These states are on this list due to reasons such as legislative ability to add GAMT, the level of interest, and the number of annual births.

    Kim Tuminello
    ACD Director of Advocacy